Trials / Completed
CompletedNCT01717664
Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS)
A Phase IIa Proof of Concept Study to Assess the Efficacy and Safety of Fixed Dose Combination RHB-104 as Add-On Therapy to Interferon Beta-1a in Patients Treated for Relapsing Remitting Multiple Sclerosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- RedHill Biopharma Limited · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The investigators hypothesize that Mycobacterium avium paratuberculosis positive Relapsing Remitting MS subjects will have a greater response to Interferon beta-1a therapy plus RHB-104 than from Interferon beta-1a alone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RHB-104 | 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine |
Timeline
- Start date
- 2013-06-01
- Primary completion
- 2015-12-01
- Completion
- 2016-07-01
- First posted
- 2012-10-30
- Last updated
- 2016-07-28
Locations
2 sites across 1 country: Israel
Source: ClinicalTrials.gov record NCT01717664. Inclusion in this directory is not an endorsement.